[Diffused suberitrodermic psoriasis induced by infliximab].
The case of a young male is described, affected by Crohn disease with reactive Spondylarthritis essay with Infliximab to the dose of 3 mg/kgs. After 15 days from the third infusion, the patient developed a first psoriasis eruption to the palm of the hands and the plant of the feet, for which was begun topical therapy with cortisone. After an initial improvement, the patient suffered a diffusion of the psoriasis eruption to the whole trunk and the limbs with a suberitrodermic aspect. The possible pathogenesis of this paradoxical effect of the anti-TNF is considered. Also being still partly the causes, is important the inhibition of the TNF-alpha with consequent expansion of the INF-alpha, in turn potential inductor of psoriasis.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D003424:Crohn Disease / Q000150:complications; D016572:Cyclosporine / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D011565:Psoriasis / Q000139:chemically induced* / Q000188:drug therapy; D012867:Skin / Q000187:drug effects*; D025241:Spondylarthritis / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000069285:Infliximab
Psoriasi suberitrodermica diffusa indotta da infliximab.